体内体外联合免疫法制备抗鼻咽癌单克隆抗体

Preparation of Monoclonal Antibodies Against Nasopharyngeal Cancer by in vivo and vitro Combining Immunization

目的】获得高特异性的抗鼻咽癌单克隆抗体。【方法】以湖南鼻咽癌细胞株HNE2细胞作免疫原 ,经体内体外联合免疫方法获得免疫脾细胞 ,并与SP2 /0骨髓瘤细胞融合获得抗鼻咽癌单克隆抗体的杂交瘤细胞系 ,用ELISA、免疫组化筛选阳性克隆。【结果】获得 10株稳定分泌抗鼻咽癌单克隆抗体的杂交瘤 ,其中HNL1和HNL5用免疫组化检测对鼻咽癌组织反应的阳性率分别为 6 0 .0 %和 6 5 .0 %。【结论】抗鼻咽癌单克隆抗体HNL1。

Objective To achieve highly specific monoclonal antibody against Nasopharyngeal Cancer (NPC). Methods Using Hunan NPC cell lines (HNE2) as immunogen, hybridoma cell lines were obtained through fusion of SP2/0 myeloma cells with immunized murine spleen cells by in vivo and vitro combining immunization. The positive clones were screened by an enzyme linked immunosorbent assay (ELISA) and indirect immunohistochemical method. Results Ten hybridoma cell lines secreting stable anti NPC monoclonal antibody were generated.As shown by indirect immunohistochemical detection, the percentages of positive reaction to NPC tissue samples were 60.0% for HNL1 and 65.0% for HNL5 respectively. Conclusion Anti NPC monoclonal antibody HNL1 and HNL5 exhibit fairly good specificity for NPC.